Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | TTR | P02766 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | TP53 | P04637 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486831 | 1.00 | MEN1 (0.73) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL6847961 | 0.95 | KDM4E (0.81) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL1810217 | 0.95 | KDM4E (0.81) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL1808386 | 0.93 | MEN1 (0.84) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL1808387 | 0.93 | MEN1 (0.84) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL2515226 | 0.87 | PTGS2 (0.61) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL19199189 | 0.86 | MEN1 (0.63) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL2574064 | 0.86 | LMNA (0.77) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL2574065 | 0.86 | LMNA (0.77) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL16130509 | 0.85 | KDM4E (0.61) | MEN1MAPTKMT2AKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | BIOMOL INTERNATIONAL L.P. (US) | 2012-07-05 | — | — | US | claimed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | claimed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230040206-A1 | Microparticle Enabled Delivery Structures, Methods of Preparing and Using Same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-09 | — | — | US | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| CN-105263583-B | Cosmetic or dermatological use of polygonum orientale extract | 巴斯夫美容护理法国公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2670404-B1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | UNIV PRINCETON (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006081329-A2 | STRATEGIES FOR DESIGNING DRUGS THAT TARGET THE SIR2 FAMILY OF ENZYMES | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | MEN1 4292/4885MAPT 3600/4885KMT2A 2695/4885 |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | SIRT1, SIRT2, SIRT7 | MEN1 2032/4885MAPT 2621/4885KMT2A 632/4885 |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | SIRT1, SIRT7, SIRT5 | MEN1 2759/4885MAPT 3039/4885KMT2A 635/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | MEN1 4727/4885MAPT 3091/4885KMT2A 3254/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | MEN1 4632/4885MAPT 3534/4885KMT2A 3278/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | MEN1 4632/4885MAPT 3534/4885KMT2A 3278/4885 |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | SIRT1, SIRT7, SIRT5 | MEN1 2759/4885MAPT 3039/4885KMT2A 635/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | MEN1 3511/4885MAPT 2805/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.